| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 04/13/2005 | EP1404293A4 Infection control system |
| 04/13/2005 | EP1365776B1 Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| 04/13/2005 | EP1259535B1 Cyclic hexapeptide derivatives |
| 04/13/2005 | EP1244641B1 Thiazolyl amide derivatives |
| 04/13/2005 | EP1242416B1 Substituted isoxazolines and their use as antibacterial agents |
| 04/13/2005 | EP1196136B1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 04/13/2005 | EP1183353B1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 04/13/2005 | EP1134222B1 IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM |
| 04/13/2005 | EP1015469B1 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| 04/13/2005 | EP0774971B1 Synthetic peptide inhibitors of hiv transmission |
| 04/13/2005 | CN1606624A Vaccines |
| 04/13/2005 | CN1606568A Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 04/13/2005 | CN1606567A Antimicrobial polypeptides from pseudoplectania nigrella |
| 04/13/2005 | CN1606563A Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 04/13/2005 | CN1606558A Novel cephalosporin compounds and process for preparing the same |
| 04/13/2005 | CN1606554A Beta-lactamyl vasopressin v1aantagonists |
| 04/13/2005 | CN1606545A Pyrrolidine and piperidine derivates as nk1 antagonists |
| 04/13/2005 | CN1606463A Methods of treating bacterial infections in dogs and cats |
| 04/13/2005 | CN1606454A Antibody targeting compounds |
| 04/13/2005 | CN1606446A Method for preventing and treating communicable diseases and other diseases using monosaccharides and disaccharides |
| 04/13/2005 | CN1606444A Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/13/2005 | CN1606433A Methods for wet granulating azithromycin |
| 04/13/2005 | CN1606427A Stable surfactant compositions for suspending components |
| 04/13/2005 | CN1605586A Alpha-substituted 2-methyl-5-nitroimidazole-1-ethanol derivatives |
| 04/13/2005 | CN1605358A Externally applied medicine for treating chronic dermatopathy |
| 04/13/2005 | CN1605335A Antivirus dihydromyricetin and myricetin containing pharmaceutical composition |
| 04/13/2005 | CN1605332A Fibrauretine injection for perfusion and its preparing process |
| 04/13/2005 | CN1196795C Novel method for preparing synthesis intermediates |
| 04/13/2005 | CN1196788C Assembly of wild-type and chimeric influenza virus-like particles (VLPS) |
| 04/13/2005 | CN1196787C Virulence genes and proteins and their use |
| 04/13/2005 | CN1196784C Promoter of human endoglin gene and its use |
| 04/13/2005 | CN1196714C Process for producing immunolobulins for intravenous administration and other immunolobulin products |
| 04/13/2005 | CN1196704C Process for preparing inhibitors of nucleoside metabolism |
| 04/13/2005 | CN1196697C Thiophene-ethyl thiourea compounds and their use in treatment of HIV |
| 04/13/2005 | CN1196687C Inhibitors of IMPDH enzyme |
| 04/13/2005 | CN1196683C Amino-compound |
| 04/13/2005 | CN1196681C (+)-Norcisapride useful for 5-HT3 and 5-HT4 mediated disorbers |
| 04/13/2005 | CN1196474C Liposome-entrapped DNA oral vaccines |
| 04/12/2005 | US6878828 Coupling cysteine with benzonitrile, then esterifying, alkylating, hydrolyzing and reacting with acids to form 2-methylcysteine |
| 04/12/2005 | US6878727 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| 04/12/2005 | US6878722 Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
| 04/12/2005 | US6878717 HIV replication inhibiting pyrimidines |
| 04/12/2005 | US6878709 Treating acute and chronic inflammatory disorders and cancer. |
| 04/12/2005 | US6878705 Especially agents against viruses of the herpes family. |
| 04/12/2005 | US6878704 Heterocyclic mutilin esters and their use as antibacterials |
| 04/12/2005 | US6878702 Anti-inflammatory agents |
| 04/12/2005 | US6878686 Cross-linked glycopeptide-cephalosporin antibiotics |
| 04/12/2005 | US6878685 Purified Tat and Nef to promote localized accumulation of CD4+ cells, and an antimicrobial chemotherapeutic agent, such as an antibiotic; may also contain tumor necrosis factor-alpha |
| 04/12/2005 | US6878541 Papilloma pseudo-virus and preparation |
| 04/12/2005 | US6878372 Methods of preventing and treating flavivirus infection in animals |
| 04/12/2005 | US6878370 Chemically modified TNF-α |
| 04/12/2005 | CA2322658C Process for synthesizing carbapenem antibiotics |
| 04/12/2005 | CA2235041C Iodine complexes in powder form |
| 04/12/2005 | CA2203936C Boronic ester and acid compounds, synthesis and uses |
| 04/12/2005 | CA2174107C Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones |
| 04/12/2005 | CA2127193C 2-[1-(1,3-thiazolin-2-yl)azetidin-3-yl] thio-carbapenem derivatives |
| 04/12/2005 | CA2108292C Process for preparing hepatitis a (hav) antigens and vaccines |
| 04/07/2005 | WO2005030955A1 Protein expressed in nk cell |
| 04/07/2005 | WO2005030774A1 Hcv inhibitors and methods of using them |
| 04/07/2005 | WO2005030771A1 Imidazopyridine-derivatives as inductible no-synthase inhibitors |
| 04/07/2005 | WO2005030770A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | WO2005030769A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | WO2005030768A1 Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors |
| 04/07/2005 | WO2005030752A1 8-cyanoquinolonecarboxylic acid derivative |
| 04/07/2005 | WO2005030233A1 Active oxygen scavenging agent and process for producing the same |
| 04/07/2005 | WO2005030224A1 Nitrosylated analgesic and/or anti-inflammatory drugs having antiviral activity |
| 04/07/2005 | WO2005030198A1 Medicinal composition for treatment for fatty liver or liver disease |
| 04/07/2005 | WO2005030194A1 Hcv inhibitiing sulfonamides |
| 04/07/2005 | WO2005021559A3 Oxazaborolidines as bacteria effectors |
| 04/07/2005 | WO2005020973A3 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine |
| 04/07/2005 | WO2005014533A3 Aryl and heteroaryl compounds, compositions, and methods of use |
| 04/07/2005 | WO2005012256A8 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 04/07/2005 | WO2005009418A3 Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| 04/07/2005 | WO2004108159A3 Gb virus c (hepatitis g virus) for the treatment of hiv |
| 04/07/2005 | WO2004096818A3 Method and compositions for identifying anti-hiv therapeutic compounds |
| 04/07/2005 | WO2004029092A8 Antibody for adcc and inducing cytokine production |
| 04/07/2005 | WO2004006847A3 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 04/07/2005 | WO2004002422A3 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 04/07/2005 | US20050075619 Container for linezolid intravenous solution |
| 04/07/2005 | US20050075511 Prevention of human and/or animal viral, bacterial, fungal or parasitic infections; plant fungicides, bactericides and/or herbicides; reduced side effects; environmentally friendly; such as ((n-formyl-n-hydroxyamino)-methoxy)-methyl phosphonic acid disodium salt |
| 04/07/2005 | US20050075483 Vancomycin derivatives linked with disaccharide sugar, obtained by deprotecting a protected glycopeptide, by sulfonation, replacement; preparing a glycopeptide by glycosylation of an aglycone derived from glycopeptide antibiotic |
| 04/07/2005 | US20050075390 HIV protease inhibitors |
| 04/07/2005 | US20050075388 Compounds as viricides for treatment of HTLV or aids |
| 04/07/2005 | US20050075382 Compounds as bactericides or drugs |
| 04/07/2005 | US20050075356 E.g., N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-1-(methylamino)ethyl]pyrimidine-4-carboxamide, used for preventing, treating or delaying the onset of and infection by AIDS |
| 04/07/2005 | US20050075348 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| 04/07/2005 | US20050075342 Pyrrolopyridazine derivatives |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075332 Tricyclic compounds with antiviral activity |
| 04/07/2005 | US20050075330 Dipeptidyl peptidase inhibitors |
| 04/07/2005 | US20050075329 S-tofisopam, a prodrug or a salt thereof, free of its R enantiomer, and a carrier; may also contain one or more other anticonvulsants |
| 04/07/2005 | US20050075326 Spiro compounds and methods for the modulation of chemokine receptor activity |
| 04/07/2005 | US20050075318 Antiviral for RNA or DNA viruses such as HIV, HBV or HSV; acyclic pyrimidine nucleoside phosphonate analogues; 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine; ; alkylating the 6-hydroxypyrimidine base with a dialkyl 2-chloroethoxymethylphosphonate |
| 04/07/2005 | US20050075309 Purine nucleoside analogues for treating Flaviviridae including hepatitis C |
| 04/07/2005 | US20050075301 Pharmaceutical preparation with RNA as hemostasis cofactor |
| 04/07/2005 | US20050075296 for extending the release times and decreasing the toxicity, by using a di-lauric acid salt of tilmicosin in an acceptable solvent, which forms a precipitate when injected into water; treating infections in dogs and cats where tilmicosin was previously too toxic |
| 04/07/2005 | US20050075273 condensation aerosols; for treatment of pain or alcohol abuse; kits |
| 04/07/2005 | US20050074758 Prokineticin polypeptides, related compositions and methods |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | US20050074507 Polyherbal formulation for hepatic and splenic disorders |